|Bid||413.52 x 800|
|Ask||414.07 x 800|
|Day's range||412.51 - 417.98|
|52-week range||288.01 - 555.77|
|Beta (5Y monthly)||0.95|
|PE ratio (TTM)||79.30|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||453.00|
ACCD, EAT, ILMN, MAXN, and TM have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2021
EU antitrust regulators have resumed their scrutiny of U.S. life sciences company Illumina's bid for Grail Inc after a two-month temporary halt and will decide by Feb. 4 whether to clear the deal, a European Commission filing showed on Tuesday. The EU competition enforcer paused its investigation on Aug. 11 while waiting for Illumina to provide requested data. Last month it sent a statement of objections to Illumina for closing the deal before securing regulatory clearance, warning of interim measures.
Shares of applied genomics company Ilumina (NASDAQ: ILMN) dropped 11.3% in September, according to data provided by S&P Global Market Intelligence. Ilumina's shares are still up more than 4% this year. The biggest thing hanging over Ilumina is its somewhat controversial purchase of liquid biopsy company Grail, which was once was a division of Ilumina but was spun off in 2016 into a separate company.